Ad
Tuesday, 29 November 2016
Momenta's Humira biosimilar succeeds in key psoriasis study
(Reuters) - U.S. biotech company Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment